Monopar Therapeutics (MNPR) Total Current Liabilities (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Total Current Liabilities data on file, last reported at $2.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 47.94% year-over-year to $2.7 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 million (down 47.94% YoY), and the FY2025 full-year result was $2.7 million, down 47.94% from the prior year.
• Total Current Liabilities climbed to $2.7 million in Q4 2025, from $2.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.3 million in Q4 2024 to a low of $806272.0 in Q1 2021.
• A 5-year average of $2.3 million and a median of $2.1 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities jumped 198.98% in 2024 and tumbled 47.94% in 2025, its largest moves.
• Tracing MNPR's Total Current Liabilities over 5 years: stood at $1.6 million in 2021, then jumped by 97.96% to $3.1 million in 2022, then plunged by 43.83% to $1.8 million in 2023, then soared by 198.98% to $5.3 million in 2024, then plunged by 47.94% to $2.7 million in 2025.
• Business Quant data shows MNPR's Total Current Liabilities at $2.7 million in Q4 2025, $2.6 million in Q3 2025, and $1.6 million in Q2 2025.